nice_老虎社区_美港股上老虎

th1s0ne
2021-10-13

nice

After-Hours Stock Movers: Apple, Qualcomm, Skyworks Solutions and more

$Regulus Therapeutics Inc$. 25% LOWER; announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease . The Company recently completed the dosing period of the in-life portion of the IND-enabling toxicity studies for RGLS8429; anticipates submitting an Investigational New Drug application ; and subject to U.S. Food and Drug Administration clearance, initiating a phase 1 study in the second quarter of 2022.$N

After-Hours Stock Movers: Apple, Qualcomm, Skyworks Solutions and more

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":822969871,"tweetId":"822969871","gmtCreate":1634085402226,"gmtModify":1634085402967,"author":{"id":3579772900389006,"authorId":3579772900389006,"authorIdStr":"3579772900389006","name":"th1s0ne","avatar":"https://static.tigerbbs.com/7eb0f4a742f6158068fdbcdd23f6740c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":44,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>nice</p></body></html>","htmlText":"<html><head></head><body><p>nice</p></body></html>","text":"nice","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/822969871","repostId":2175377341,"repostType":4,"repost":{"id":"2175377341","pubTimestamp":1634081700,"share":"https://www.laohu8.com/m/news/2175377341?lang=&edition=full","pubTime":"2021-10-13 07:35","market":"us","language":"en","title":"After-Hours Stock Movers: Apple, Qualcomm, Skyworks Solutions and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2175377341","media":"StreetInsider","summary":"$Regulus Therapeutics Inc$.  25% LOWER; announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease . The Company recently completed the dosing period of the in-life portion of the IND-enabling toxicity studies for RGLS8429; anticipates submitting an Investigational New Drug application ; and subject to U.S. Food and Drug Administration  clearance, initiating a phase 1 study in the second quarter of 2022.$N","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/RGLS\">Regulus Therapeutics Inc</a>. (Nasdaq: RGLS) 25% LOWER; announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Company recently completed the dosing period of the in-life portion of the IND-enabling toxicity studies for RGLS8429; anticipates submitting an Investigational New Drug application (IND); and subject to U.S. Food and Drug Administration (FDA) clearance, initiating a phase 1 study in the second quarter of 2022.</p>\n<p><a href=\"https://laohu8.com/S/STIM\">Neuronetics Inc.</a> (NASDAQ: STIM) 19.8% LOWER; provided preliminary revenue results for the third quarter of 2021. The Company expects total revenue for the third quarter to be approximately $13.8 million, compared to previously issued guidance of $15.0 million to $16.0 million. The Company now expects full-year revenue to be in the range of $53.3 million to $54.3 million.</p>\n<p><a href=\"https://laohu8.com/S/RZLT\">Rezolute, Inc.</a> (Nasdaq: RZLT) 11% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering, and, in lieu of common stock, Rezolute intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock.</p>\n<p><a href=\"https://laohu8.com/S/JSPR\">Jasper Therapeutics</a> (NASDAQ: JSPR) 7.6% HIGHER; Oppenheimer initiates coverage with an Outperform rating and $21 price target.</p>\n<p><a href=\"https://laohu8.com/S/VST\">Vistra Energy Corp.</a> (NYSE: VST) 6.5% HIGHER; announced a new $2 billion share repurchase program and the pricing of a private offering of 1,000,000 shares of its 8% Series A Fixed-Rate Reset Cumulative Redeemable Perpetual Preferred Stock to qualified institutional buyers</p>\n<p><a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a>, Inc. (Nasdaq: SRPT) 6% LOWER; announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of its common stock in an underwritten public offering. Sarepta also intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 in shares of its common stock.</p>\n<p><a href=\"https://laohu8.com/S/NAPA\">The Duckhorn Portfolio, Inc.</a> (NYSE: NAPA) 5.2% LOWER; announced the commencement of an underwritten public offering of 12,000,000 shares of its common stock by certain of its stockholders.</p>\n<p><a href=\"https://laohu8.com/S/APEN\">Apollo Endosurgery, Inc.</a> (NASDAQ: APEN) 4.3% LOWER; intends to offer and sell shares of its common stock in an underwritten public offering. All of the common stock is being offered by Apollo. In addition, Apollo expects to grant the underwriters a 30-day option to purchase additional shares of common stock.</p>\n<p><a href=\"https://laohu8.com/S/PYCR\">Paycor HCM, Inc.</a> (NASDAQ: PYCR) 3.4% LOWER; announced the commencement of a public offering of its common stock by certain selling stockholders (the Offering). The selling stockholders are offering 12,000,000 shares of Paycors common stock pursuant to a registration statement on Form S-1 (the Registration Statement) filed with the Securities and Exchange Commission (the SEC).</p>\n<p><a href=\"https://laohu8.com/S/EFC\">Ellington Financial LLC</a> (NYSE: EFC) 3.1% LOWER; announced today that it has commenced an underwritten public offering of 5,000,000 shares of common stock. The Company also expects to grant the underwriters an option for 30 days to purchase up to an additional 750,000 shares of common stock. <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> &amp; Co. LLC, BofA Securities, J.P. Morgan, UBS Securities LLC and Keefe, Bruyette &amp; Woods, A Stifel Company are acting as joint book-running managers for the offering.</p>\n<p><a href=\"https://laohu8.com/S/SWKS\">Skyworks Solutions</a> (NASDAQ: SWKS) 2% LOWER; Apple product cuts due to chip shortages.</p>\n<p><a href=\"https://laohu8.com/S/SBRA\">Sabra Health Care</a> (Nasdaq: SBRA) 2% LOWER; announced today that it has commenced an underwritten public offering of 6.8 million shares of its common stock. Sabra intends to grant the underwriters a 30-day option to purchase up to 1.02 million additional shares of its common stock.</p>\n<p><a href=\"https://laohu8.com/S/CRUS\">Cirrus Logic</a> (NASDAQ: CRUS) 1.6% LOWER; Apple product cuts due to chip shortages.</p>\n<p><a href=\"https://laohu8.com/S/AAPL\">Apple</a> (NASDAQ: AAPL) 1.5% LOWER; is likely to slash its projected iPhone 13 production targets for 2021 by as many as 10 million units because of prolonged chip shortages, according to Bloomberg, citing people with knowledge of the matter.</p>\n<p><a href=\"https://laohu8.com/S/AVGO\">Broadcom</a> (NASDAQ: AVGO) 1.4% LOWER; Apple product cuts due to chip shortages.</p>\n<p><a href=\"https://laohu8.com/S/QCOM\">Qualcomm</a> (Nasdaq: QCOM) 1.4% HIGHER; announced after the close that its Board of Directors has approved a new $10.0 billion stock repurchase authorization, in addition to its July 18 stock repurchase program with a remaining $0.9 billion of repurchase authority.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Apple, Qualcomm, Skyworks Solutions and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Apple, Qualcomm, Skyworks Solutions and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-13 07:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19052512><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nRegulus Therapeutics Inc. (Nasdaq: RGLS) 25% LOWER; announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19052512\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NAPA":"The Duckhorn Portfolio, Inc.","EFC":"Ellington投资","QCOM":"高通","VST":"Vistra Energy Corp.","RGLS":"Regulus Therapeutics Inc","APEN":"Apollo Endosurgery, Inc.","RZLT":"Rezolute, Inc.","STIM":"Neuronetics Inc.","JSPR":"Jasper Therapeutics","SWKS":"思佳讯","SRPT":"Sarepta Therapeutics","PYCR":"Paycor HCM, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19052512","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175377341","content_text":"After-Hours Stock Movers:\nRegulus Therapeutics Inc. (Nasdaq: RGLS) 25% LOWER; announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Company recently completed the dosing period of the in-life portion of the IND-enabling toxicity studies for RGLS8429; anticipates submitting an Investigational New Drug application (IND); and subject to U.S. Food and Drug Administration (FDA) clearance, initiating a phase 1 study in the second quarter of 2022.\nNeuronetics Inc. (NASDAQ: STIM) 19.8% LOWER; provided preliminary revenue results for the third quarter of 2021. The Company expects total revenue for the third quarter to be approximately $13.8 million, compared to previously issued guidance of $15.0 million to $16.0 million. The Company now expects full-year revenue to be in the range of $53.3 million to $54.3 million.\nRezolute, Inc. (Nasdaq: RZLT) 11% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering, and, in lieu of common stock, Rezolute intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock.\nJasper Therapeutics (NASDAQ: JSPR) 7.6% HIGHER; Oppenheimer initiates coverage with an Outperform rating and $21 price target.\nVistra Energy Corp. (NYSE: VST) 6.5% HIGHER; announced a new $2 billion share repurchase program and the pricing of a private offering of 1,000,000 shares of its 8% Series A Fixed-Rate Reset Cumulative Redeemable Perpetual Preferred Stock to qualified institutional buyers\nSarepta Therapeutics, Inc. (Nasdaq: SRPT) 6% LOWER; announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of its common stock in an underwritten public offering. Sarepta also intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 in shares of its common stock.\nThe Duckhorn Portfolio, Inc. (NYSE: NAPA) 5.2% LOWER; announced the commencement of an underwritten public offering of 12,000,000 shares of its common stock by certain of its stockholders.\nApollo Endosurgery, Inc. (NASDAQ: APEN) 4.3% LOWER; intends to offer and sell shares of its common stock in an underwritten public offering. All of the common stock is being offered by Apollo. In addition, Apollo expects to grant the underwriters a 30-day option to purchase additional shares of common stock.\nPaycor HCM, Inc. (NASDAQ: PYCR) 3.4% LOWER; announced the commencement of a public offering of its common stock by certain selling stockholders (the Offering). The selling stockholders are offering 12,000,000 shares of Paycors common stock pursuant to a registration statement on Form S-1 (the Registration Statement) filed with the Securities and Exchange Commission (the SEC).\nEllington Financial LLC (NYSE: EFC) 3.1% LOWER; announced today that it has commenced an underwritten public offering of 5,000,000 shares of common stock. The Company also expects to grant the underwriters an option for 30 days to purchase up to an additional 750,000 shares of common stock. Morgan Stanley & Co. LLC, BofA Securities, J.P. Morgan, UBS Securities LLC and Keefe, Bruyette & Woods, A Stifel Company are acting as joint book-running managers for the offering.\nSkyworks Solutions (NASDAQ: SWKS) 2% LOWER; Apple product cuts due to chip shortages.\nSabra Health Care (Nasdaq: SBRA) 2% LOWER; announced today that it has commenced an underwritten public offering of 6.8 million shares of its common stock. Sabra intends to grant the underwriters a 30-day option to purchase up to 1.02 million additional shares of its common stock.\nCirrus Logic (NASDAQ: CRUS) 1.6% LOWER; Apple product cuts due to chip shortages.\nApple (NASDAQ: AAPL) 1.5% LOWER; is likely to slash its projected iPhone 13 production targets for 2021 by as many as 10 million units because of prolonged chip shortages, according to Bloomberg, citing people with knowledge of the matter.\nBroadcom (NASDAQ: AVGO) 1.4% LOWER; Apple product cuts due to chip shortages.\nQualcomm (Nasdaq: QCOM) 1.4% HIGHER; announced after the close that its Board of Directors has approved a new $10.0 billion stock repurchase authorization, in addition to its July 18 stock repurchase program with a remaining $0.9 billion of repurchase authority.","news_type":1},"isVote":1,"tweetType":1,"viewCount":412,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}